2,537,558 Shares in Senti Biosciences, Inc. (NASDAQ:SNTI) Bought by 8Vc Gp I LLC

8Vc Gp I LLC bought a new position in shares of Senti Biosciences, Inc. (NASDAQ:SNTI) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 2,537,558 shares of the company’s stock, valued at approximately $1,675,000. Senti Biosciences makes up about 1.7% of 8Vc Gp I LLC’s investment portfolio, making the stock its 2nd biggest position. 8Vc Gp I LLC owned 5.70% of Senti Biosciences at the end of the most recent quarter.

Separately, ARK Investment Management LLC grew its holdings in shares of Senti Biosciences by 7.9% in the 4th quarter. ARK Investment Management LLC now owns 1,969,860 shares of the company’s stock worth $1,300,000 after acquiring an additional 143,785 shares during the period. Institutional investors own 25.73% of the company’s stock.

Senti Biosciences Stock Down 3.1 %

Shares of SNTI traded down $0.01 on Friday, reaching $0.34. The stock had a trading volume of 82,385 shares, compared to its average volume of 180,336. The firm has a 50-day moving average of $0.36 and a 200 day moving average of $0.42. The firm has a market capitalization of $15.56 million, a PE ratio of -0.24 and a beta of 2.88. Senti Biosciences, Inc. has a twelve month low of $0.27 and a twelve month high of $1.10.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.26) earnings per share for the quarter. Senti Biosciences had a negative return on equity of 79.71% and a negative net margin of 2,692.82%. On average, sell-side analysts anticipate that Senti Biosciences, Inc. will post -1 earnings per share for the current fiscal year.

Senti Biosciences Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.